Journal of Research in Ayurvedic Sciences

Register      Login

Table of Content

2017 | April-June | Volume 1 | Issue 2

RESEARCH ARTICLE

Pitta Srinivas, Sanjaykumar Giri, Sneha Marlewar, Bhagwan Sahai Sharma

Clinical Efficacy and Safety of Chyavanaprasha on Aging in Apparently Healthy Elderly Subjects: A Prospective, Open-label, Multicenter Study

[Year:2017] [Month:April-June] [Volume:1] [Number:2] [Pages:9] [Pages No:81 - 89]

PDF  |  DOI: 10.5005/jp-journals-10064-0008  |  Open Access |  How to cite  | 

Abstract

Introduction: Aging is a persistent decline in an individual\'s physiological and structural attributes with time, and geriatric care has become a top specialty. Ayurveda has suggested regimes for graceful aging and it is included under the spectrum of Rasayana therapy. Chyavanaprasha is a preparation that has been mentioned in the classics as an excellent rejuvenator with ability to delay aging and enhance general wellbeing. Objective: To evaluate the efficacy and safety of Chyavanaprasha in improving general body health and quality of life (QOL) in apparently healthy elderly subjects. Materials and methods: A prospective open-label multiple center clinical study was carried out at three peripheral centers of the Central Council for Research in Ayurvedic Sciences and 214 subjects satisfying the selection criteria were enrolled and were administered Chyavanaprasha Lehyam 12 gm twice daily before food with milk for 12 weeks and the effect of the drug was assessed at intervals of 14 days up to 84 days. Paired sample t-test was used to compare mean change in functional exercise capacity by 6 minutes walk test (MWT) and changes in QOL using World Health Organization (WHO) QOL BREF scale from baseline to the 84th day. A p-value of <0.05 was considered significant. Results: Statistically significant improvement was observed in WHO QOL BREF score (p-value <0.001) and functional exercise capacity: Blood sugar, serum cholesterol, kidney function test, and liver function test (LFT) were within normal limits during the entire trial. No adverse drug reaction or adverse event was reported during the trial period. Conclusion: Chyavanaprasha administered in the abovementioned dose was found effective and safe in apparently healthy elderly subjects in improving their QOL.

RESEARCH ARTICLE

Sushmita P Otta, S Indira Kumari, Rajesh Sannd, Neera Vyas, Bharti

Clinical Efficacy of Ayurvedic Formulations Rajahpravartini Vati, Varunadi Kashaya and Kanchanar Guggulu in the Management of Polycystic Ovary Syndrome: A Prospective, Open-label, Multicenter Study

[Year:2017] [Month:April-June] [Volume:1] [Number:2] [Pages:9] [Pages No:90 - 98]

PDF  |  DOI: 10.5005/jp-journals-10064-0009  |  Open Access |  How to cite  | 

Abstract

Introduction: Polycystic ovary syndrome (PCOS) is characterized by oligo-anovulation, clinical or biochemical hyperandrogenism, and polycystic ovaries. It is a metabolic disorder and around 4 to 9% of women of reproductive age are affected by it. Objective: To evaluate the clinical usefulness of Rajahpravartini Vati, Varunadi Kashaya, and Kanchanar Guggulu in the management of PCOS and changes in the quality of life (QOL) of PCOS women. Materials and methods: It was a multicenter single-arm prospective study. Sixty women aged between 18 and 40 years with PCOS confirmed as per Rotterdam criteria 2003, i.e., hyperandrogenism clinically (hirsutism)/or biochemically (elevated serum testosterone concentrations), anovulation/ or oligomenorrhea, or amenorrhea after negative screening pregnancy test and/or polycystic ovary were included in the study. Ayurvedic regimen comprising Rajahpravartini Vati (250 mg), Kanchanar Guggulu (500 mg), and Varunadi Kashaya (20 mL) was administered with lukewarm water twice daily for 180 days. The outcome measures were attainment of normal menstrual cycle length, changes on acne score, hirsutism (Ferriman–Gallwey score), and improvement in QOL of women with PCOS. Results: The trial drugs have statistically significant effect (p < 0.001) on the signs and symptoms, i.e., oligomenorrhea, presence of body hair. The drugs have significant effects on reducing the number of cysts in both the ovaries (p-value < 0.001) and also improvement in QOL of the women studied. There was no adverse event reported during the study period and all laboratory safety parameters were within the normal range. Conclusion: Rajahpravartini Vati, Varunadi Kashaya, and Kanchanar Guggulu have shown a positive role for the treatment of PCOS and to improve the QOL of the subjects and clinically safe to use.

RESEARCH ARTICLE

Rajesh Sannd, Banmali Das, HML Meena, Omraj Sharma, Harbans Singh, BR Meena, SK Sharma, VB Kumavat, GC Bhuyan

Clinical Safety of Selected Ayurvedic Formulations in Iron Deficiency Anemia

[Year:2017] [Month:April-June] [Volume:1] [Number:2] [Pages:9] [Pages No:99 - 107]

PDF  |  DOI: 10.5005/jp-journals-10064-0010  |  Open Access |  How to cite  | 

Abstract

Introduction: Anemia is a condition in which the number of red blood cells (RBCs) or their oxygen-carrying capacity is insufficient to meet physiologic needs of the body and is characterized by a constellation of symptoms. Ayurveda compares the symptoms of anemia with that of the disease Pandu. Punarnavadi Mandura, Dadimadi Ghrta, Navayasa Churna, and Dhatri Lauha are few among the multitudes of medicines that are currently prevalent in use for the management of Pandu. However, the safety of these drugs were not evaluated until now through clinical drug trials. Objective: Critical analysis and presentation of clinical safety and efficacy outcomes of classical Ayurvedic formulations, viz., Dhatri Lauha, Navayasa Churna, Punarnavadi Mandura, and Dadimadi Ghrta in iron deficiency anemia (IDA). Materials and methods: A retrospective analysis of data collected from three different clinical studies that had been completed in peripheral institutes of Central Council for Research in Ayurvedic Sciences (CCRAS) were critically evaluated to assay the safety profile of four drugs, namely Dhatri Lauha, Navayasa Churna, Punarnavadi Mandura, and Dadimadi Ghrta in patients of IDA. Safety assessments were done through analyzing liver function test (LFT) and renal function test before and after the trial period. Paired sample t-test was used to compare the mean changes from baseline to the end of the trial period. A p-value of <0.05 was considered significant. Drug compliance and adverse drug reaction (ADR)/adverse events (AE), if any, were noted. Conclusion: The findings in the three different clinical studies clearly reveal that Punarnavadi Mandura, Navayasa Churna, Dhatri Lauha, and Dadimadi Ghrta are clinically safe, effective, and tolerable.

RESEARCH ARTICLE

Bikratan Das, Sangeeta Sangvikar, Shashi Ghosh, AK Jain, GK Swami, Saiprasad, Alok Srivastav, DS Sahu, Tapasi Borah, MM Rao, VB Kumawat, Pitta Srinivas, KK Singh, SK Mehar, Rajesh Kumari

Clinical Safety of Selected Ayurvedic Formulations in Rheumatoid Arthritis

[Year:2017] [Month:April-June] [Volume:1] [Number:2] [Pages:9] [Pages No:108 - 116]

PDF  |  DOI: 10.5005/jp-journals-10064-0011  |  Open Access |  How to cite  | 

Abstract

Introduction: Rheumatoid arthritis (RA) is a chronic systemic autoimmune inflammatory disease which mainly affects the small joints leading to erosion of cartilage and bone associated with irreversible joint damage, joint deformity, and systemic complications. The symptoms of RA resemble with the signs and symptoms mentioned in Amavata described in different texts of Ayurveda. Simhanada Guggulu, Brihat Saindhavadya Taila, Vatari Guggulu, Rasna Saptaka Kashaya, and Hingvashtaka Churna are commonly used in the management of this disease. However, the safety data are not collected on these formulations till now. Objective: Critical analysis and presentation of clinical safety outcomes of classical Ayurvedic formulations Simhanada Guggulu, Brihat Saindhavadya Taila, Vatari Guggulu, Rasna Saptaka Kashaya, and Hingvashtaka Churna in patients of RA generated through multicenter open label studies at different Central Council for Research in Ayurvedic Sciences (CCRAS) centers. Materials and methods: Data were collected from three different clinical studies executed in peripheral institutes of CCRAS and were critically evaluated to assay the safety profile of five formulations. Safety assessments were done through analyzing liver function tests (LFTs) and kidney function tests (KFTs) before and after the study trial period. Conclusion: The findings in the three different clinical studies clearly indicate that Simhanada Guggulu, Brihat Saindhavadya Taila, Vatari Guggulu, Rasna Saptaka Kashaya, and Hingvashtaka Churna are clinically safe and tolerable in the participants belonging to different age groups, gender, geographical area, and different prakrti.

RESEARCH ARTICLE

BR Meena, Omraj Sharma, Harbans Singh, SK Sharma, VB Kumavat, Rajesh Sannd, GC Bhuyan, Bhagwan Sahai Sharma

Clinical Efficacy and Safety of Navayasa Churna in the Management of Iron Deficiency Anemia

[Year:2017] [Month:April-June] [Volume:1] [Number:2] [Pages:8] [Pages No:117 - 124]

PDF  |  DOI: 10.5005/jp-journals-10064-0012  |  Open Access |  How to cite  | 

Abstract

Iron deficiency anemia (IDA) is a condition where deficiency of iron in the body leads to reduction in the number of red blood cells (RBC). Even though IDA is an easily manageable condition with excellent outcome, it is observed that modern iron preparation often irritates gastric mucosa and causes adverse effects. In Ayurveda, IDA can be correlated with pandu based on symptomatic similarity. Navayasa Churna is an iron containing herbomineral preparation used for the management of Pandu. In this study, clinical efficacy and safety of Navayasa Churna has been evaluated in IDA. Aims and objectives: To evaluate clinical efficacy and safety of Navayasa Churna in IDA. Materials and methods: An open-labeled multicenter prospective clinical trial was conducted at Ayurveda Regional Research Institute, Mandi; M.S. Regional Ayurveda Central Research Institute, Jaipur; and the National Institute of Ayurvedic Pharmaceutical Research, Patiala. Patients with IDA (n = 150) belonging to either sex, with hemoglobin in the range of 8 to 10%, aged between 18 and 50 years and with serum ferritin <30 mg/dL, and blood smear depicting microcytic, hypochromic state were selected. Navayasa Churna was given 1 gm (2 capsules of 500 mg each) twice daily with water for 90 days with a follow-up period of 1 month without drug. Assessment was done based on the relief in clinical symptoms of IDA and hematological parameters. Safety assessment was done through analysis of liver function tests (LFTs) and kidney function tests (KFTs) before and after the trial period. Results: The formulation showed significant relief in cardinal symptoms of anemia and also in hemoglobin level. No adverse events/effects were was noted during trial period. The values of LFT and KFT were observed to be within limits during the entire period. Conclusion: Navayasa Churna in the above-mentioned dose and duration was found effective and safe in patients suffering from IDA.

SHORT COMMUNICATION

Narayanam Srikanth

CCRAS Vision Document 2030: A Short Appraisal

[Year:2017] [Month:April-June] [Volume:1] [Number:2] [Pages:6] [Pages No:125 - 130]

PDF  |  DOI: 10.5005/jp-journals-10064-0013  |  Open Access |  How to cite  | 

Abstract

Central Council for Research in Ayurvedic Sciences (CCRAS), Ministry of AYUSH, Government of India, has formulated and projected “CCRAS Vision Document 2030” with a strategy of research and development for research outcomes in next 15 years considering the strength of Ayurveda and current unmet medical needs. The core components of the document comprise sustainable development goals (SDGs) of CCRAS for vision 2030 for 15 years, 7 years strategy (long-term vision), and 3 years action document, fundamentally harmonized with the goals and recommendations of major national and international health policy documents.